Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01FY Combinations of monoclonal antibodies and antibody drug conjugates
L01FY01 Pertuzumab and trastuzumab
D11934 Pertuzumab, trastuzumab and hyaluronidase <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Monoclonal Antibody/Antibody-Drug Conjugate
Hyaluronidase/ Pertuzumab/ Trastuzumab
D11934 Pertuzumab, trastuzumab and hyaluronidase
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D11934 Pertuzumab, trastuzumab and hyaluronidase
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11934
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11934